Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01581138 · ClinicalTrials.gov registry record · Phase 2
VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
A Phase 2 study of Chronic Hepatitis C Virus, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 18
- Study locations
NCT01581138: Completed Phase 2 study of Chronic Hepatitis C Virus, sponsored by Vertex Pharmaceuticals Incorporated.
NCT01581138 is a Phase 2 study of Chronic Hepatitis C Virus that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 64 participants, below the 342-participant average among 3 other Chronic Hepatitis C Virus trials with a reported enrollment target (81% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01581138, a Phase 2 study of Chronic Hepatitis C Virus, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of two all oral regimens in subjects who have chronic hepatitis C and have not received treatment yet.
Conditions Studied
Interventions
- DRUG ribavirin
- DRUG telaprevir
- DRUG VX-222
Study Locations (18)
California
- - Anaheim
- - Riverside
- - San Diego
North Carolina
- - Asheville
- - Winston-Salem
Tennessee
- - Germantown
- - Nashville
Texas
- - Austin
- - San Antonio
Alabama
- - Birmingham
Colorado
- - Englewood
Florida
- - Orlando
Georgia
- - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT01581138 record still lists
NCT01581138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 342-participant average among 3 other Chronic Hepatitis C Virus trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Chronic Hepatitis C Virus appearing as the primary indexed condition, and to 3 interventions - of which ribavirin is the first listed.
NCT01581138 lists 18 locations in 13 states (California, North Carolina, Tennessee).
Frequently Asked Questions
What is clinical trial NCT01581138 about?
NCT01581138 is a clinical study titled "VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C". The purpose of this study is to evaluate the efficacy and safety of two all oral regimens in subjects who have chronic hepatitis C and have not received treatment yet.
What is the current status of trial NCT01581138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2012-07. Estimated completion is 2013-12.
What conditions does trial NCT01581138 study?
This clinical trial studies the following conditions: Chronic Hepatitis C Virus.
What interventions are being tested in trial NCT01581138?
The interventions under investigation include: ribavirin (DRUG), telaprevir (DRUG), VX-222 (DRUG).
Who is sponsoring clinical trial NCT01581138?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01581138 being conducted?
This trial has 18 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
-
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
COMPLETED · Phase 3
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia